A Phase 1/2 interventional study of SRX246 and Placebo in Intermittent Explosive Disorder, sponsored by Azevan Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-07-21.
Sponsored by Azevan Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Disruptive, Impulse Control, and Conduct Disorders · United States.
Among the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1/2, and was the 18th registered.
56 studies on the registry are indexed under Disruptive, Impulse Control, and Conduct Disorders; 17 are open to participants now.
Browse Disruptive, Impulse Control, and Conduct Disorders studies →8 of the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 21–55 · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 21–60
Ohio State University · Sites in United States
Ages 21–55 · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
The University of Texas at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Disruptive, Impulse Control, and Conduct Disorders studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 2 · Phase 4 4
First in 1999; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 48 across 46 interventional studies indexed under Disruptive, Impulse Control, and Conduct Disorders.
Median enrollment 48 across the 28 interventional studies, 48 across the 3 observational. Of the 22 that completed or were terminated, 12 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 31 have an industry lead sponsor. The 10 most frequent:
Azevan Pharmaceuticals is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Azevan Pharmaceuticals has 1 study filed under Disruptive, Impulse Control, and Conduct Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05895513Ohio State UniversityPimavanserin and Aggression and Social Cognition. | 2027-01 |
| NCT06237868West Virginia UniversityrTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease | 2027-05 |
| NCT06118567Ohio State UniversityEffect of Nitrous Oxide on Aggression. | 2027-08-31 |
| NCT05712057Duke UniversityNeurostimulation Versus Therapy for Problems With Emotions | 2027-10-31 |
| NCT06639594M.D. Anderson Cancer CenterFeasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study | 2027-11-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED).
Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will be randomized to either SRX246 or Placebo treatment groups.
Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits throughout the trial. The study results will be determined based on any changes observed over the study period.
This exploratory Phase II study has been designed to examine the safety and tolerability profile, and to compare the activity of the novel V1a vasopressin antagonist (SRX246) against placebo, in adults with DSM-5 Intermittent Explosive Disorder (IED).
Adult Male and Female subjects with a current DSM-5 diagnosis of IED will be enrolled. All subjects will undergo systematic diagnostic assessment for DSM-5 Axis I and II disorders. Subjects with DSM-5 IED (without current, co-morbid, DSM-5 Major Depression) whose: (a) Life History of Aggression (LHA) score is > 12, (b) Overt Aggression Scale Modified (OAS-M) "Irritability" score is > 6 and, (c) screening OAS-M "Aggression" score is > 15, will be entered into a two-week baseline lead-in phase.
After the lead-in phase, study subjects who continue to meet OAS-M criteria will be randomized to one of the two (2) treatment conditions and stratified by gender so that equal numbers of males and females are assigned to SRX246 and Placebo Groups. Those who do not meet the criteria will exit the protocol at that time. Treatment Conditions: (a) 8-week course of SRX246 (4 weeks at 120 mg bid, and 4 weeks at 160 mg bid) or (b) 8-week course of Placebo, followed by a one-week "taper" to withdraw subjects from study medication.
IED subjects in all conditions will have structured diagnostic interview sessions and questionnaires administered throughout the trial. Blinding to treatment condition will be maintained by using different personnel for these activities. Analysis of a change from baseline in the diagnostic measures will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
Drug: SRX246
Placebo capsules to match the amount of SRX246 capsules for 8 weeks
Drug: Placebo
capsules
Safety and Tolerability
measured as the number of participants with adverse events
Time frame: from initial dose of intervention until completion of the study up to 8 weeks
Overt Aggression Scale Modified (OAS-M) Total Aggression Score
Change from Baseline OAS-M Score. Higher values represent a worse outcome. The OAS-M contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of aggressive behavior in a week.
Time frame: Comparison of baseline score to score at end of treatment period of 8 weeks
| Milestone | SRX246 | Placebo |
|---|---|---|
| Started | 49 | 48 |
| Completed | 39 | 40 |
| Not completed | 10 | 8 |
measured as the number of participants with adverse events
| participants | SRX246 | Placebo |
|---|---|---|
| adverse events (AE) | 28 | 21 |
| serious adverse events (SAE) | 0 | 0 |
Change from Baseline OAS-M Score. Higher values represent a worse outcome. The OAS-M contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of aggressive behavior in a week.
| score on a scale | SRX246 | Placebo |
|---|---|---|
| Overt Aggression Scale Modified (OAS-M) Total Aggression Score | -29.55 ± 37.343 | -30.43 ± 34.082 |
Collected over from first dose of study drug to last follow-up visit, up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SRX246 | 0/49 (0%) | 0/49 (0%) | 9/49 (18.4%) |
| Placebo | 0/48 (0%) | 0/48 (0%) | 7/48 (14.6%) |
| Event | SRX246 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 3/49 | 3/48 |
| DiarrheaGastrointestinal disorders | 3/49 | 2/48 |
| Dry MouthGastrointestinal disorders | 3/49 | 2/48 |
| Age, Categorical(Participants) | SRX246 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 49 | 48 | 97 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | SRX246 | Placebo | Total |
|---|---|---|---|
| Female | 20 | 20 | 40 |
| Male | 29 | 28 | 57 |
| Ethnicity (NIH/OMB)(Participants) | SRX246 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 45 | 43 | 88 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | SRX246 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 29 | 31 | 60 |
| White | 16 | 12 | 28 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(Participants) | SRX246 | Placebo | Total |
|---|---|---|---|
| United States | 49 | 48 | 97 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of May 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SRX246
Disruptive, Impulse Control, and Conduct Disorders →
Azevan Pharmaceuticals